Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

17.48 +0.59 (+3.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bicara Therapeutics Inc. - Common Stock

< Previous 1 2 Next >

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript ↗

August 18, 2026

Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis.

Via The Motley Fool

Topics Earnings

Bicara Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of...

Via MarketBeat

Topics Earnings

Top movers in Friday's after hours session ↗

July 31, 2026

Via Chartmill

Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗

May 11, 2026

Via Chartmill

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗

June 13, 2026

This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.

Via The Motley Fool

Topics Regulatory Compliance

Bicara (BCAX) Q4 2025 Earnings Transcript ↗

June 01, 2026

Bicara (BCAX) Q4 2025 Earnings Transcript

Via The Motley Fool

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗

May 22, 2026

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...

Via MarketBeat

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗

May 15, 2026

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

Via The Motley Fool

Topics Regulatory Compliance

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗

May 15, 2026

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗

May 14, 2026

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development...

Via MarketBeat

Bicara (BCAX) Q1 2026 Earnings Transcript ↗

May 11, 2026

Bicara (BCAX) Q1 2026 Earnings Transcript

Via The Motley Fool

Bicara Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...

Via MarketBeat

Topics Earnings

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗

May 04, 2026

This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.

Via The Motley Fool

Topics Regulatory Compliance

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗

March 30, 2026

This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗

March 26, 2026

This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.

Via The Motley Fool

Topics Regulatory Compliance

These stocks that are showing activity before the opening bell on Monday. ↗

October 13, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...

Via Benzinga

Topics ETFs Stocks

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 04, 2025

Via Benzinga

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? ↗

May 23, 2025

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

May 23, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 23, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

May 23, 2025

Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook ↗

May 23, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

May 23, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results ↗

May 23, 2025

Via Benzinga

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗

May 23, 2025

The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.

Via Investor's Business Daily

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

May 23, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.